Pamela Stephenson Sells 3,137 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider Pamela Stephenson sold 3,137 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total value of $171,217.46. Following the completion of the sale, the insider now owns 69,529 shares in the company, valued at approximately $3,794,892.82. This represents a 4.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Disc Medicine Stock Up 0.3 %

Shares of NASDAQ:IRON opened at $54.52 on Friday. The firm has a market cap of $1.62 billion, a P/E ratio of -13.70 and a beta of 0.73. Disc Medicine, Inc. has a 12 month low of $25.60 and a 12 month high of $77.60. The company’s 50-day moving average price is $59.05 and its two-hundred day moving average price is $55.10.

Analyst Upgrades and Downgrades

IRON has been the topic of several recent analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $90.00 price target (up previously from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Raymond James upgraded shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $66.00 to $110.00 in a research note on Monday, November 4th. Morgan Stanley raised shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 target price on the stock in a report on Tuesday, November 5th. Scotiabank lifted their price target on shares of Disc Medicine from $70.00 to $73.00 and gave the company a “sector outperform” rating in a report on Wednesday, January 22nd. Finally, Stifel Nicolaus boosted their price target on shares of Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, January 24th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $88.90.

Institutional Trading of Disc Medicine

Several hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its position in Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock worth $52,000 after purchasing an additional 266 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Disc Medicine by 45.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after buying an additional 337 shares during the period. Teacher Retirement System of Texas raised its position in shares of Disc Medicine by 8.9% during the fourth quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company’s stock worth $308,000 after acquiring an additional 396 shares during the last quarter. Sterling Capital Management LLC lifted its stake in shares of Disc Medicine by 798.4% during the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock valued at $36,000 after acquiring an additional 503 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Disc Medicine by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company’s stock valued at $400,000 after acquiring an additional 593 shares during the period. 83.70% of the stock is owned by institutional investors.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.